Aurinia Pharmaceuticals Inc

News & Events

Press Releases

In The Media

1. Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025

   Business Wire MAY 5, 2025 6:00 AM EDT
   Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will...
   READ ARTICLE

2. Glass Lewis Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General Meeting

   Business Wire APR 30, 2025 6:00 AM EDT
   Aurinia Pharmaceuticals Inc. (“Aurinia” or the “Company”) (NASDAQ: AU...
   READ ARTICLE

3. ISS Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General Meeting

   Business Wire APR 29, 2025 6:00 AM EDT
   Aurinia Pharmaceuticals Inc. (“Aurinia” or the “Company”) (NASDAQ: AU...
   READ ARTICLE

4. Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress

   Business Wire FEB 27, 2025 6:00 AM EST
   Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and t...
   READ ARTICLE

5. Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025

   Business Wire FEB 20, 2025 4:05 PM EST
   Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will...
   READ ARTICLE

6. Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis

   Business Wire NOV 18, 2024 5:53 PM EST
   New Guidelines Presented at ACR Convergence 2024 Recommend First-Line Therapy with LUPKYNIS &#x...
   READ ARTICLE

7. Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024

   Business Wire NOV 15, 2024 6:00 AM EST
   Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), announced today the accepta...
   READ ARTICLE

8. Aurinia to Participate in Jefferies London Healthcare Conference

   Business Wire NOV 14, 2024 6:00 AM EST
   Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Com...
   READ ARTICLE

9. Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth

   Business Wire NOV 7, 2024 6:10 AM EST
   Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it has ...
   READ ARTICLE

10. Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development

    Business Wire NOV 7, 2024 6:00 AM EST
    Achieved $67.8 million in total net revenue and $55.5 million in net product revenue for the thir...
    READ ARTICLE